Categories
Report

NYSE: ATNM Profile

Actinium Pharmaceuticals, Inc.

OUR NEW PROFILE IS:   (NYSE: ATNM)

_______________________

H.C. WAINWRIGHT & CO. PLACES $53.00 TARGET ON THIS $14 CLINICAL-STAGE BIOPHARMA STOCK INDICATING MASSIVE POTENTIAL UPSIDE

ACTINIUM-225 BASED ALPHA THERAPIES HAVE TREATED APPROXIMATELY 150 PATIENTS TREATED ACROSS SIX PHASE 1 AND PHASE 2 CLINICAL TRIALS

ACTINIUM ANNOUNCES POSITIVE FULL DATA RESULTS FROM THE PIVOTAL PHASE 3 SIERRA TRIAL IN PATIENTS WITH ACTIVE, RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

READ THE INVESTOR PRESENTATION HERE

________________________________

Hello Everyone,

We want you to pull up ATNM immediately.

This is a company that we have profiled in the past before.

2023 has been a great year so far for the company as you can tell by the chart above.

There are a lot of moving parts to this profile but we want to zero in on one particular catalyst to start.

Over the weekend the company announced:

ACTINIUM ANNOUNCES POSITIVE FULL DATA RESULTS FROM THE PIVOTAL PHASE 3 SIERRA TRIAL IN PATIENTS WITH ACTIVE, RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

–  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm

–  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients

–  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001

–  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover

–  Iomab-B was well tolerated with a favorable safety profile – 4 times lower rate of sepsis than control arm

–  Company to host conference call and webcast on Saturday, February 18, 2023 at 6:00 PM EST to highlight full SIERRA results

NEW YORK, Feb. 18, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive results for the primary and secondary endpoints from its pivotal Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission following BMT with a high degree of statistical significance (p<0.0001). Additionally, Iomab-B produced a significant and clinically meaningful improvement in the secondary endpoint of Event-Free Survival (EFS), with a 78% reduction in the probability of an event (Hazard Ratio=0.22, p<0.0001). Iomab-B doubled 1-year survival compared to the control arm excluding cross over patients (26.1% vs 13.1%) as well as median overall survival (6.4 months vs. 3.2 months). Iomab-B was well tolerated with four times lower rates of sepsis (6.1% vs 28.6%) and lower rates of febrile neutropenia, mucositis and acute graph versus host disease (aGVHD). Iomab-B enabled unprecedented access to BMT with 100% engraftment in patients receiving a therapeutic dose of Iomab-B compared to 18% of patients in the control arm and Iomab-B produced a 75% post-BMT Complete Remission (CR) rate compared to 6.3% post-BMT CR in the control arm. These high rates of access and post-BMT CR enabled the highly significant primary endpoint results. The full SIERRA results were presented in the late-breaker session at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).

…………….. I would be paying close attention in the morning to this one.

ANALYST COVERAGE:

According to TipRanks.com, on February 7, 2023, H.C. Wainwright analyst Joseph Pantginis reiterated coverage on Actinium Pharmaceuticals Inc. (NYSE: ATNM) with a target of $53.00.(28)

TARGET RANGE:

According to Barchart.com, shares of Actinium Pharmaceuticals Inc. (NYSE: ATNM) bounced off their 52 week low of $4.41 on 3/15/2022 indicating there could be an upside potential of 1,100% if they were to move from their 52 week low and reach the $53.00 target set by H.C. Wainwright. Not that a move to $53.00 is certain, but the potential upside needs to be noted. (28)

POTENTIAL FOR GROWTH:

Historically, small-cap stocks have outperformed large-cap stocks. A small-cap stock is generally that of a company with a market capitalization of between $300 million and $2 billion. And because they are smaller, small-cap stock share prices typically have a greater chance of growth. (29) As of 2/10/2023, the market capitalization Actinium Pharmaceuticals Inc. (NYSE: ATNM) is just over $309M according to MarketWatch.com. (31)

POSSIBLE ACQUISITION CANDIDATE:

Small cap companies are acquired more frequently than larger companies. Large companies can enter new markets or gain intellectual property by buying smaller businesses. Large companies usually pay a premium to acquire growth firms. (32) An acquisition announcement is not expected, but the potential needs to be noted.

INTELLECTUAL PROPERTY:

The company’s clinical pipeline was developed from its Antibody Warhead Enabling (“AWE”) technology platform, which is protected by over 195 issued and pending patents, trade secrets and know-how that Actinium Pharmaceuticals Inc. (NYSE: ATNM) is applying to the development of targeted radiotherapies for blood and solid tumor indications, independently and with collaborators. (33)

PIPELINE:

The company is advancing its pipeline of clinical-stage development programs that they believe can improve patient access to potentially curative treatments and improve patient outcomes. To the best of its knowledge, Actinium Pharmaceuticals Inc. (NYSE: ATNM) is developing the most advanced multi-indication, clinical-stage radiotherapy pipeline for targeted conditioning. In addition, the company believes they have the most experience with Actinium-225 based alpha therapies with approximately 150 patients treated across six Phase 1 and Phase 2 clinical trials. (33)

FDA APPLICATION:

In 2023, Actinium Pharmaceuticals Inc. (NYSE: ATNM) intends to submit a Biologics License Application (BLA) seeking approval for Iomab-B to address patients aged 55+ with r/r AML who cannot access bone marrow transplants (BMT) with currently available therapies. Iomab-B has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and has patent protection into 2037.(33)

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or two world-changing drugs or therapies for billion-dollar markets. (32) One of these biotech stocks, Actinium Pharmaceuticals Inc (ATNM) just received a $53.00 target indicating a potential upside of approx. 328% according to Benzinga.(27)

(27)

IF ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM) IS ABLE TO REACH THE $53.00 TARGET SET BY H.C. WAINWRIGHT ANALYST JOSEPH PANTGINIS, WE COULD WITNESS AN UPSIDE POTENTIAL OF APPROX. 1,100% AFTER BOUNCING OFF ITS 52-WEEK LOW OF $4.41… (28)(29)

2

(35)

Listen. Nothing is certain. But look at the Actinium Pharmaceuticals Inc. (NYSE: ATNM) daily chart above and do a little technical analysis using StockCharts.com. You can see the following moving averages:(35)

• Daily average price is: $13.00 (as of 2/10/23)

• 50-day moving average at $10.89

• 200-day moving average is $7.98

Shares of Actinium Pharmaceuticals Inc. (NYSE: ATNM) are trading over its 50-day moving average price of $10.89 and 200-day moving average price of $7.98 (as of 2/10/2023).

On that same day, (ATNM) reached an intraday high of $13.00 meaning shares have already moved over 194% since bouncing off its 52-week low of $4.41 which was set on 3/15/2022 according to BarChart.com. (29)

If shares of Actinium Pharmaceuticals Inc. (NYSE: ATNM) reached the $53.00 target set by H.C. Wainwright analyst Joseph Pantginis, we could witness a potential move of approx. 1,100% after bouncing off its 52-week low of $4.41… (28,29)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM)’S POTENTIAL FOR GROWTHTHE TERM SMALL CAP REFERS TO STOCKS WITH A SMALL MARKET CAPITALIZATION, BETWEEN $300 MILLION AND $2 BILLION. STOCKS WITH A MARKET CAP BELOW $300 MILLION ARE REFERRED TO AS MICRO CAPS, AND THOSE BELOW $50 MILLION ARE CALLED NANO CAPS.(32)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is just over $309M according to MarketWatch.com. (31)

Small-cap stocks can trade on any exchange. However, the majority of them are found on the Nasdaq or the OTCBB. That should not be surprising, as those exchanges have more lenient listing requirements.(32)

However, Actinium Pharmaceuticals Inc. (NYSE: ATNM) trades on the NYSE, which is typically reserved for more established companies. (37)

Merger and acquisition activity provides another opportunity for small-cap companies. (32)

Small caps are acquired more frequently than larger companies.

Large companies can enter new markets or gain intellectual property by buying smaller businesses.

Actinium Pharmaceuticals Inc. (NYSE: ATNM) has over 195 issued and pending patents in its intellectual property portfolio.(33)

Acquisitive companies usually pay a premium to acquire growth firms, leading to profits as soon as a deal is announced publicly.

Undervalued small companies can also make tempting takeover targets, especially when they are selling for below book value.(32)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and clinical experience to develop novel targeted radiotherapies for patients with unmet needs.(33) 

The company’s targeted radiotherapies combine the cell-killing ability of radiation via a radioisotope payload with a targeting agent, such as a monoclonal antibody, to deliver radiation in a precise manner inside the body to specific, targeted cells such as cancer cells, to potentially achieve greater efficacy with lower toxicity than with cytotoxic chemotherapy or external beam radiation. (33) 

Targeted radiotherapies also enable the broader application of radiation than external beam radiation as they can be used in the treatment of both solid tumors and blood cancers, which generally cannot be treated with external radiation given their diffuse nature. CD45 and CD33 are both expressed in multiple hematologic cancers, which are known to be highly sensitive to radiation. (33) 

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s clinical programs against these targets are focused on two primary areas: (33)

• targeted conditioning prior to a bone marrow transplant (“BMT”), adoptive cell therapy (“ACT”) such as CAR-T or gene therapy with Iomab-B and

• targeted radiotherapy combinations with Actimab-A and other therapeutic agents.

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s most advanced clinical development program is Iomab-B, a CD45 targeting radiotherapy being developed to enable patients with blood cancers and other conditions to receive cellular and gene therapies. Iomab-B is being studied in the pivotal Phase SIERRA trial to enable a bone marrow transplant (“BMT”) in patients with active, relapsed, or refractory acute myeloid leukemia (“r/r AML”) age 55 and above, a patient population not considered eligible for BMT, which is the only potentially curative treatment option, with current approaches. (33)

On October 31, 2022, Actinium Pharmaceuticals Inc. (NYSE: ATNM) announced that Iomab-B met the primary endpoint of the SIERRA trial with a high degree of statistical significance (p<0.0001). (33)

The trial was conducted in patients 55 years of age or older with r/r AML who typically cannot access a potentially lifesaving bone marrow transplant (BMT) as they are deemed unfit and thus unable to tolerate standard chemotherapy-based conditioning. (33)

Trial results showed that with Iomab-B conditioning, these patients have increased access to a BMT with a clinically meaningful duration of complete remission, along with a favorable safety profile, potentially establishing a new treatment option for the majority of the 10,000 r/r AML patients in the U.S. who are deemed unfit for BMT with current approaches.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s second most advanced clinical program is Actimab-A, a CD33 targeting radiotherapy that we are developing as a therapeutic to be used in combination with the company’s treatment modalities to leverage the potential synergistic mechanism of targeted radiation. (33) 

program

(33)

Actimab-A is being studied in a Phase 1/2 combination trial with the salvage regimen CLAG-M in patients with r/r AML fit for intensive therapy and in a Phase 1/2 combination trial with Venetoclax, a targeted therapy, in patients with r/r AML who are both fit and unfit for intensive therapy.

On November 3, 2022, Actinium Pharmaceuticals Inc. (NYSE: ATNM) announced that Phase 1 results from the Actimab-A CLAG-M trial were accepted for oral presentation at the American Society of Hematology (“ASH”) Annual Meeting & Symposium on December 10, 2022. (33)

The study enrolled patients with r/r AML with a median age of 63, 2 lines of prior therapies (range: 1- 5), and 67% had adverse cytogenetics with 52% having a TP53 mutation. Prior treatment included BMT in 57% and prior Venetoclax therapy in 57% of patients. This patient population has dismal survival outcomes and outside of this novel combination clinical trial, would not be treated with CLAG-M. There was a 67% overall response rate (“ORR”) across all dose cohorts and an 83% ORR at the recommended Phase 2 dose (“RP2D”). (33) 

Overall, 72% of patients achieving a Complete Remission (“CR”) or Complete Remission with incomplete count recovery (“CRi”) were minimal residual disease (“MRD”) negative and 83% of patients receiving the RP2D were “MRD negative.” (33) 

Median overall survival was 12 months with a 53% 1-year overall survival rate and 32% 2-year overall survival rate. (33) 

To provide context for this analysis, the median OS in patients who relapse post Venetoclax is less than 3 months and the median OS in patients who relapse with a TP53 mutation is less than 2 months.

Data from our Actimab-A Venetoclax combination trial has been accepted for poster presentation at ASH. This trial is exploring the potential mechanistic synergy we elucidated in preclinical models, that depleting Mcl-1 via targeted radiation from Actimab-A can re-sensitize or reduce resistance to Venetoclax.

Actinium Pharmaceuticals Inc. (NYSE: ATNM) has observed responses including a CR in early-dose cohorts. This trial is ongoing with dose escalation and scheduling optimization ongoing. The company expects to present proof of concept from the Phase 1 portion of this study in 2023. (33) 

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is studying Iomab-ACT, a low-dose version of Iomab-B, for conditioning before CAR-T cellular therapy in collaboration with Memorial Sloan Kettering Cancer Center, which is funded by the National Institutes of Health (“NIH”) grant. The company has completed the treatment of an initial cohort of 3 patients and will expand to a second cohort. (33) 

Actinium Pharmaceuticals Inc. (NYSE: ATNM) expects to present proof of concept data from this study in 2023.

THE ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM) PATENTS

FDA

(39)

7

The Actinium Pharmaceuticals Inc. (NYSE: ATNM) clinical pipeline has been developed from the company’s Antibody Warhead Enabling (“AWE”) technology platform, which is protected by over 195 issued and pending patents, trade secrets, and know-how that the company is applying to the development of targeted radiotherapies for blood and solid tumor indications, independently and with collaborators. (33)(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is also utilizing its AWE technology platform to advance its research objectives focused on developing next-generation targeted radiotherapies with its expanded research and development organization and research laboratories leveraging its drug development experience. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM)’ S PIPELINE (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is advancing a pipeline of clinical-stage development programs that it believes can improve patient access to potentially curative treatments and improve patient outcomes. To the best of the company’s knowledge, it is developing the most advanced multi-indication, clinical-stage radiotherapy pipeline for targeted conditioning.(33)

In addition, the company believes it has the most experience with Actinium-225-based alpha therapies with approximately 150 patients treated across six Phase 1 and Phase 2 clinical trials. (33)

(33)

The Actinium Pharmaceuticals Inc. (NYSE: ATNM) product development strategy is actively informed by clinical data with our drug candidates Iomab-B, Actimab-A, and Iomab-ACT in approximately 600 patients and 19 clinical trials, including the Pivotal Phase 3 SIERRA trial for Iomab-B, 12 prior clinical trials with Iomab-B at the Fred Hutchinson Cancer Research Center, 6 trials with Actimab-A and the MSKCC/NIH trial with Iomab-ACT. (33)

(33)

The company is applying its clinical experience to address unmet patient needs with its programs: (33)

Targeted Conditioning Programs for Cell and Gene Therapy: Iomab-B and Iomab-ACT are intended to potentially enable improved access and outcomes to cell-based therapies with curative potential, including BMT, ACT, and gene therapy. (33)

Conditioning in the context of BMT, ACT, or gene therapy is the act of depleting certain blood and immune-forming cells, including bone marrow stem cells and, in some cases, cancer cells prior to transplanting new cells into a patient. Currently, conditioning is accomplished using a combination of cytotoxic chemotherapeutic agents and external radiation. (33)

These non-targeted conditioning regimens are highly toxic and may prevent a patient from receiving a potentially curative therapy and hinder outcomes.

Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes its targeted conditioning agents have the potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while sparing normal healthy cells, resulting in potentially lower systemic and off-target toxicities. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) intends to develop its targeted conditioning programs for BMT, ACT, and gene therapy applications for malignant and non-malignant diseases and believes that multiple radioisotopes may be utilized including alpha and beta emitters. (33)

Actinium-225 Based Therapeutic Backbone Therapy Program in AML: The company’s Actimab-A program demonstrates its leadership in the clinical development of Ac-225 therapeutics, as it focuses this industry-leading alpha-isotope based radiotherapy program as a backbone therapy for novel combinations in r/r AML. (33)

Actimab-A is the first radiotherapeutic for r/r AML and has the unique value proposition of broad applicability, a differentiated mechanism of action, and targeted precision that is well-tolerated with minimal toxicity. Specifically, Actimab-A targets CD33, which is expressed in virtually all AML patients regardless of cytogenetics or mutations and enables potent alpha radiation to be directed against radiosensitive AML cells that have no known resistance or repair mechanism when hit with the Ac-225 isotope payload that causes double-stranded breaks in DNA. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes that Actimab-A in combination with chemotherapy, targeted agents, or immunotherapy, in r/r AML as a backbone therapy, represents a significant opportunity to improve patient outcomes in AML and is developing its product candidates according to this strategy. (33)

Platform Collaborations and Preclinical Programs: The company is leveraging its clinical experience, robust intellectual property, and radiotherapy know-how through research collaborations and its own preclinical development programs. Through the company’s research collaborations, such as with Astellas, they are advancing into solid tumor indications. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) can utilize the ability of radioisotopes to be used for diagnostic purposes as well as therapeutics, which are referred to as theranostics. (33)

The company is also exploring novel targeted radiotherapies in solid tumors and blood cancers such as HER3 expressing solid tumors in collaboration with AVEO and combinations with immunotherapies such as CD47 immune checkpoint inhibitors with EpicentRx. (33)

DEVELOPMENT STRATEGY FOR RELAPSED AND REFRACTORY AML(33)

We are developing Iomab-B and Actimab-A to holistically address the unmet needs of both fit and unfit patients with AML, initially targeting the estimated 10,000 patients with relapsed or refractory disease. (33)

These patients are largely treated in approximately 100 centers and a majority of the BMTs are done in the top 50 centers. There is virtually total overlap between the top 50 BMT centers and the top 100 AML treatment centers. (33)

By developing two targeted radiotherapies for this indication, Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes it can address a significant number of patients at various stages of their disease and treatment journey. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes it can produce operating leverage through synergies in the supply chain and commercialization across both drug candidates. (33)
In addition, the company believes both Iomab-B and Actimab-A have the potential to be used in other blood cancer indications. (33)

(33)

Iomab-B enables patients with r/rr AML with active disease, who cannot tolerate intensive therapy and who otherwise would not be considered for BMT, to receive a potentially curative BMT. (33)

The SIERRA trial demonstrated the ability of Iomab-B conditioning to enable 100% of patients to proceed to BMT and achieve rapid engraftment resulting in significantly higher rates of patients with Complete Remissions and durable Complete Remissions. (33)

The tolerable safety profile of Iomab-B and efficacy as shown in SIERRA trial could transform the treatment paradigm for r/r AML.

12

For r/r AML patients requiring salvage therapy, Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes combinations based on its Actimab-A alpha therapy have the potential to improve patient outcomes. The company is combining Actimab-A with CLAG-M for patients fit for intensive therapy in a Phase 1 trial conducted at the Medical College of Wisconsin (“MCW”). (33)

(33)

This novel combination trial enrolled patients who otherwise would not be considered for CLAG-M and added Actimab-A to precisely target and kill any residual AML cells following treatment with CLAG-M. (33)

The Actimab-A CLAG-M combination has a manageable safety profile and produced high response rates, high rates of MRD negativity and 53% 1- year and 32% 2-year median overall survival in a cohort of heavily pretreated patients with adverse cytogenetics, including 52% of patients who had a TP53 mutation. (33)

These survival outcomes represent a significant improvement over current dismal survival rates in these very hard-to-treat patients and support continued development. (33)

13

(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is studying Actimab in combination with Venetoclax for patients who are both unfit and fit for intensive therapy. Venetoclax is approved in combination with HMAs, and the company believes Actimab-A has a more synergistic mechanism and that its targeted nature can produce better patient outcomes than Venetoclax HMA combinations. (33)

They are currently conducting a multi-center Phase 1/2 trial of this novel combination and are optimizing the dosing regimen for the anticipated Phase 2 portion of the trial. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM)’S LEAD CANDIDATE AND TARGETED CONDITIONING AGENT: IOMAB-B (33)

Iomab-B (I-131 apamistamab), the company’s lead candidate and targeted conditioning agent is comprised of the anti-CD45 monoclonal antibody known as apamistamab (formerly BC8) and the radioisotope Iodine-131 (“I-131”). Iomab-B is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously and rapidly depleting blood cancer, immune and bone marrow stem cells that uniquely express CD45. CD45 is an antigen expressed on leukemia, lymphoma and myeloma cancer cells, but is not expressed outside of the hematopoietic, or blood-forming system.(33)

This unique expression on blood cancer and immune cells enables simultaneous depletion of both cell types, making CD45 an optimal antigen for targeted conditioning applications. (33)

CD45 is a cell surface antigen with an average expression of 200,000 copies per cell, however, it only internalizes at a rate of 10-15%. (33)
Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes its targeted radiotherapy approach is the most effective method to target CD45 positive cells, as the radioisotope payload linear energy transfer can readily ablate a targeted cell without requiring payload internalization like an antibody-dr-ug conjugate or without relying on biological effector function processes like a naked antibody. (33)

Developed at the Fred Hutchinson Cancer Research Center, a pioneer in the field of BMT, Iomab-B is supported by data in six disease indications including leukemias, lymphomas, and multiple myeloma, which afflict over 100,000 patients annually. Studied in over 400 patients, prior studies with Iomab-B have demonstrated nearly universal access to BMT, increased survival and tolerability in multiple clinical trials including the recently completed pivotal Phase 3 SIERRA trial in patients with active leukemic blasts >5%, relapsed or refractory acute myeloid leukemia age 55 and above. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM)’S PIVOTAL PHASE 3 SIERRA TRIAL (33)

The pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) is a 153-patient, randomized, multi-center clinical trial, studying Iomab-B compared to the control arm of physician’s choice of salvage therapy. (33)

14

(33)

Patients with active, r/r AML are not considered eligible for BMT with current approaches, and the SIERRA trial is the only randomized Phase 3 trial to offer BMT as a treatment option for this patient population. (33)

The SIERRA trial compares outcomes of patients randomized to receive Iomab-B and a BMT (the “study arm”) to those patients randomized to receive a physician’s choice of salvage therapy (the “control arm”). (33)

The control arm is also defined as conventional care, as no standard of care exists for this patient population, and includes over 20 agents that may be used as single agents or in combination including Venetoclax, a targeted Bcl-2 inhibitor, Midostaurin, and Sorafenib, targeted FLT3 inhibitors, hypomethylating agents and cytotoxic chemotherapies.(33)

Patients who fail to achieve a Complete Remission (“CR”) on the control arm are ineligible to proceed to a BMT, but the trial design permits these patients to “cross over” to receive the study arm treatment if they meet the eligibility criteria. The primary endpoint of the SIERRA trial is durable Complete Remission (“dCR”) of 180 days and the secondary endpoints are Overall Survival (“OS”) and Event Free Survival (“EFS”). (33)

On October 31, 2022, Actinium Pharmaceuticals Inc. (NYSE: ATNM) announced positive topline results from the SIERRA trial that Iomab-B met the study’s dCR primary endpoint with a high degree of statistical significance (p<0.0001). (33)

Data from full patient enrollment in the SIERRA trial (153 patients), was previously presented at several key meetings including; the Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in April 2022 and at ASH. (33)

The meetings highlighted that 100% of the patients (66/66) on the study arm received a therapeutic dose of Iomab-B received a BMT, with a median time to BMT of 30 days, and all patients achieved neutrophil and platelet engraftment in a median time of 18 days despite a high median blast count of 30%. (33)

15

(34)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) intends to submit a Biologics License Application (BLA) in 2023, seeking approval for Iomab-B to address patients aged 55+ with r/r AML who cannot access BMT with currently available therapies. Iomab-B has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and has patent protection into 2037.(33)

If approved, Actinium Pharmaceuticals Inc. (NYSE: ATNM) expects its initial commercial launch will target the leading 50-100 BMT and medical centers that perform the vast majority of BMTs in the United States. (33)

16

(33)

In the European Union (“EU”), the company received favorable feedback from the European Medicines Agency (“EMA”) via their scientific advice program that the trial design, primary endpoint, and planned statistical analysis from the SIERRA trial are acceptable as the basis for a Marketing Authorization Application, or MAA. (33)

Additionally, the European Medicines Agency (EMA) commented that it does not anticipate the need for further standalone preclinical toxicology or safety studies. (33)

Overall, transplant procedures in the EU are approximately fifty percent higher than in the United States with a similar market dynamic, with a majority of BMT volume being conducted in a concentrated number of leading medical centers. (33)

In April 2022, Actinium Pharmaceuticals Inc. (NYSE: ATNM) entered into a license and supply agreement with Immedica Pharma AB, or Immedica, pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B in the European Economic Area, Middle East and North Africa, including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya. Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. (3)

17

(33)

Upon signing, Actinium Pharmaceuticals Inc. (NYSE: ATNM) was entitled to an upfront payment of $35 million from Immedica, which they received in May 2022. Under the terms of the agreement, we are eligible to receive regulatory and commercial milestone payments and we are entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that may result from the License Agreement. Actinium Pharmaceuticals Inc. (NYSE: ATNM) will continue to be responsible for certain clinical development activities and the manufacturing of Iomab-B and will retain commercialization rights in the U.S. and the rest of the world. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM)’S IOMAB-ACT (33)

The company’s Iomab-ACT program is intended for targeted conditioning prior to ACT or gene therapy and uses the same I-131-apamistamab construct as Iomab-B at varying doses. (33)

At lower doses of one-eighth to one-sixth of the myeloablative dose, it is applicable for lymphodepletion prior to CAR-T or certain gene therapy applications where stem cell myeloablation is not necessary. At higher doses, it is applicable for gene therapy applications where stem cell myeloablation is necessary. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes its Iomab-ACT program is highly differentiated when compared to Fludarabine and Cyclophosphamide (“Flu/Cy”) or other chemotherapy-based regimens that are used as the standard of practice today for lymphodepletion prior to CAR-T. (33)

CD45 is an antigen expressed on certain immune cell types that are relevant to the mechanism of CAR-T therapies including lymphocytes, regulatory T-cells, and macrophages that have been associated with clinical responses that may limit the safety, efficacy, and durability of response of these CAR-T therapies including cytokine release syndrome (“CRS”) and neurotoxicity. Some of these limitations may be attributable to the chemotherapy-based conditioning agents that are being used prior to CAR-T therapies. (33)

18

(33)

Unlike chemotherapy, Iomab-ACT is targeted in nature and due to this CD45-directed targeting, the company expects it can improve CAR-T cell expansion, potentially resulting in responses that are more durable, but also resulting in reduced CAR-T related toxicities.(33)

Importantly, Actinium Pharmaceuticals Inc. (NYSE: ATNM) expects the Iomab-ACT program construct to enable lymphodepletion through a single-dose, outpatient administration versus Flu/Cy or other chemotherapy-based lymphodepletion regimens that can require multiple infusion cycles over several days. (33)
Because of this potentially superior profile, the Iomab-ACT construct could result in improved access to CAR-T therapy and better outcomes. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM) INVOLVED IN FIRST-OF-ITS-KIND STUDY (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is studying Iomab-ACT in a clinical collaboration with Memorial Sloan Kettering Cancer Center (“MSKCC”) for targeted conditioning prior to administration of MSKCC’s 19-28z CD19, targeting CAR-T in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (“ALL”) or diffuse large B-cell lymphoma (“DLBCL”). (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) received grant funding from the National Institute of Health (“NIH”) to fund this trial with MSKCC being a co-recipient of this grant. This is a first-of-its-kind study to use an ARC-based conditioning regimen with CAR-T therapy. The hypothesized rationale for this study is that Iomab-ACT will exert an anti-tumor effect on the chemotherapy-refractory B-ALL cells that are sensitive to radiation, resulting in reduced disease burden and simultaneously deplete CD45 expressing immune cells implicated in CAR-T-related toxicities, resulting in an optimal homeostatic environment for the CAR-T cells. (33)

The study will evaluate the feasibility of using a targeted radiotherapy-based conditioning regimen with CAR-T therapy and will evaluate safety measures including the incidence of CRS and neurotoxicity and efficacy measures, including responses and survival outcomes.

Actinium Pharmaceuticals Inc. (NYSE: ATNM) expects proof of concept data from this study in 2023. (33) In addition, Actinium Pharmaceuticals Inc. (NYSE: ATNM) is working in collaboration with the University of California Davis to utilize Iomab-ACT conditioning with a novel anti-HIV autologous gene therapy. The company continues to identify additional gene therapies for which Iomab-ACT can be used for targeted conditioning with the goal of collaborating with multiple academic or industry developers to establish Iomab-ACT as a non-chemotherapy universal targeted conditioning solution (33)

ACTINIUM-225 BASED THERAPEUTIC BACKBONE THERAPY PROGRAM IN AML (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s CD33 Alpha program is evaluating the clinical utility of Actimab-A, comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (“Ac-225”). (33)

CD33 is expressed in the majority of patients with AML and myelodysplastic syndrome (“MDS”) as well as approximately one-third of patients with multiple myeloma. Ac-225 emits four alpha particles and can kill a cell with one alpha-particle hit, making it one of the most powerful cell-killing agents with no known resistance mechanism to the double-strand DNA breaks it can cause.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) sources Ac-225 from the Department of Energy’s Oak Ridge National Laboratory. The company’s CD33 development program is driven by data obtained from over 150 treated patients, including results from a Phase 1/2 trial that studied Actimab-A as a single agent at multiple dose levels in 58 patients with newly diagnosed AML, which was completed in 2018, as well as trials studying Actimab-A in combination with other agents.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes that radiation delivered internally via a targeting moiety can be synergistic when used in combination with chemotherapy, targeted agents, and immunotherapy based on mechanistic rationales supported by our own clinical data, preclinical research, and scientific and clinical evidence in the literature. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) has prioritized its efforts and resources in favor of combination trials for our CD33 program development strategy, rather than single agent trials at this time as we believe Actimab-A can be a backbone therapy in AML when combined with other therapeutic modalities. (33)

The company’s CD33 development program encompasses the following ongoing trials:

Actimab-A + CLAG-M (33)

Actimab-A combined with CLAG-M has been studied in a Phase 1 combination trial that was conducted in collaboration with the Medical College of Wisconsin in patients aged 18 and above with r/r AML. CLAG-M (cladribine, cytarabine, filgrastim, and mitoxantrone) is a salvage chemotherapy regimen routinely used to treat patients with r/r AML. Data from the Phase 1 combination trial of Actimab-A + CLAG-M has been accepted for an oral presentation at ASH in December 2022. (33)

Patients enrolled in this study were a median of 63 years of age and were heavily pretreated with a median of 2 lines of prior treatment (range: 1-5) with 55% of patients receiving prior Venetoclax therapy and 55% receiving a prior BMT. Patients had high-risk cytogenetics with 67% having adverse features including 52% having a TP53 mutation. In addition, 52% of patients had secondary AML. Patients with r/r AML with a TP53 mutation have an expected median OS of 2 months and r/r AML patients who relapse after Venetoclax therapy have an expected survival of 2.4 months. Patients with these characteristics would not typically be considered for CLAG-M therapy outside of this clinical trial of the novel Actimab-A combination. (33)

In the 21 patients evaluable for a response who received Actimab-A CLAG-M, median 1-year overall survival is 53% and 2-year overall survival is 32%. These survival results are in conjunction with a 72% rate of minimal residual disease (“MRD) negativity. (33)

In patients receiving the recommended Phase 2 dose, an 83% overall response rate (“ORR”) and 75% MRD negativity rate were achieved. (33)
Based on these positive results, Actinium Pharmaceuticals Inc. (NYSE: ATNM) is working to develop a regulatory and development pathway for the Actimab-A CLAG-M combination and will be evaluating potential registration-enabling strategies. (33)

In addition, Actinium Pharmaceuticals Inc. (NYSE: ATNM) believes this Actimab-A + CLAG-M combination study has provided proof of principle that the addition of Actimab-A to other AML therapies can lead to well-tolerated regimens with improved responses and survival, which supports its Actimab-A backbone therapy strategy for patients with AML.(33)

ACTIMAB-A + VENETOCLAX

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is also conducting a Phase 1/2 trial combining Actimab-A with the Bcl-2 inhibitor Venetoclax in both fit and unfit patients age 18 and above with relapsed or refractory AML. (33)

This multi-center trial is being led by UCLA Medical Center. This combination is supported by mechanistic evidence in preclinical studies using Venetoclax -resistant AML tumor cell lines. (33)

In these models, Actinium Pharmaceuticals Inc. (NYSE: ATNM) has demonstrated that Actimab-A can deplete Mcl-1 and Bcl-XL, two proteins implicated in mediating resistance to Venetoclax, in addition to causing potentially lethal double-stranded DNA breaks in these CD33 expressing cells. (33)

Furthermore, in vivo studies in animal models of Venetoclax-resistant AML demonstrated robust tumor regression and improved survival in cohorts receiving the Actimab-A Venetoclax combination compared to Venetoclax alone. (33)

The rationale for this clinical study is that the addition of Actimab-A will;
1) have a direct anti-tumor effect via double-stranded DNA breaks and
2) deplete Mcl-1 and Bcl-XL making the AML cells more susceptible to Venetoclax. (33)

The Actimab-A Venetoclax combination has been well tolerated with responses, including a CR and a partial response in early dose escalation cohorts.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is continuing dose escalation and evaluating the appropriate dose sequence to determine its strategy for the Phase 2 portion of this study. (33) Proof of concept for this novel combination is expected in early 2023 (33)

ANTIBODY WARHEAD ENABLING TECHNOLOGY PLATFORM(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s proprietary AWE technology platform is supported by intellectual property, know-how, and trade secrets that cover the generation, development, methods of use and manufacture of targeted radiotherapies and certain of their components.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s AWE technology patent portfolio presently includes 43 patent families comprised of over 195 issued patents and pending patent applications, of which 10 are issued and 37 are pending in the United States, and 144 are issued or pending internationally.(33)

The effective lives of the issued patents in the company’s portfolio, or patents that may issue from the pending applications in its portfolio, range from expirations between 2024 and 2042. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s technology enables the direct labeling, or conjugation and labeling, of a biomolecular targeting agent to a radionuclide warhead and its development and use as a therapeutic regimen for the treatment of diseases such as cancer. The company’s AWE intellectual property covers various methods of use in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) has particular expertise in utilizing the alpha-emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with its alpha-emitter-based therapies, “gold standard” linker technology and 5 issued patents in the United States and 49 patents internationally related to the manufacturing or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized methods.(33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM)’s research is focused on applying its AWE technology platform to the development of radiation conjugates and to execute on research collaborations. The company’s R&D efforts employ a multidisciplinary approach leveraging its team’s knowledge and experience in cancer cell biology, radiochemistry, radiation sciences, immunology, and oncology drug development. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) intends to focus on generating targeted radiotherapies using our existing intellectual property, evaluating assets for in-licensing to complement our existing clinical pipeline, and securing collaborations and partnerships with biopharmaceutical companies. By adding research and development capabilities to its clinical development and clinical supply chain capabilities, they seek to enable the rapid translation of radiotherapies. (33)

The company’s AWE technology platform is being utilized in its ongoing research collaboration with Astellas to arm select targeting agents owned by Astellas with the alpha-emitting radioisotope Ac-225 for the development of theranostics for solid tumor indications, which combine the ability of radioisotopes to be used for both diagnostic and therapeutic purposes. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is also collaborating with AVEO Oncology (“AVEO”) to develop a targeted radiotherapy against ErbB3, also known as HER3, with the Ac-225 isotope for solid tumor indications. (33)

HER3 is overexpressed in several solid tumor indications with high unmet needs, including colorectal, gastric, head and neck, breast, ovarian, melanoma, prostate and bladder cancers with HER3 agents under development demonstrating activity in preclinical and clinical studies. (33)
To the company’s knowledge, this is the first HER3 targeting radiotherapy in development. AVEO is developing high-affinity antibodies including HER3 targeting AV-203, which has demonstrated preclinical activity across a number of solid tumor indications and was studied in Phase 1 open-label trial in patients with advanced solid tumors where it was found to be safe and generally well tolerated. (33)

In April 2022, Actinium Pharmaceuticals Inc. (NYSE: ATNM) presented data at the AACR Annual Meeting showing potent tumor cell cytotoxicity, enhanced antitumor effects, and significantly improved survival with an Ac-225 radiolabeled HER3 antibody compared to a naked HER3 antibody in a preclinical NSCLC model. The company is continuing to explore the feasibility of this approach as part of the partnership. (33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM) COLLABORATES ON NEXT-GEN SMALL-MOLECULE IMMUNOTHERAPY (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) is also collaborating with EpicentRx to evaluate Actimab-A in combination with EpicentRx’s RRx-001in AML. (33)

EpicentRx’s RRx-001, currently under investigation in a Phase 3 trial for Small Cell Lung Cancer and in other oncology and non-oncology indications, is a versatile next-generation small molecule immunotherapeutic that targets the CD47-SIRPα axis and the NLRP3 inflammasome to alter the tumor microenvironment and optimize immune response. (33)

This collaboration will explore the mechanistic synergy of RRx-001’s CD47–SIRP downregulation with Actinium’s targeted radiotherapy calreticulin upregulation to increase the immune detection and destruction of cancer cells. Preclinical experiments have begun exploring this combination in AML models. Actinium Pharmaceuticals Inc. (NYSE: ATNM) intends to leverage its experience with CD47 targeting agents such as magrolimab in this collaboration. Based on Actimab-A and RRx-001 both being clinical-stage assets, the company believes there is a potentially faster pathway to clinical trials with this novel combination, particularly if the preclinical safety and efficacy profile is in line with what was observed with Actimab-A and magrolimab. (33)

Actinium Pharmaceuticals Inc. (NYSE: ATNM) also utilized AWE to create a HER2-targeting radiotherapy using the antibody Trastuzumab with either Ac-225 or Lu-177 radioisotopes to study in combination with magrolimab for solid tumors. (33)

Anti-CD47 monotherapies, such as magrolimab, have not shown meaningful responses in clinical studies in solid tumors. The company hypothesized that radiation directed at HER2-expressing cells would upregulate cell surface calreticulin, a pro-phagocytic “eat me” signal, that when combined with an anti-CD47 blockade therapy would enhance antitumor activity. (33)

The combination of the Ac-225 or Lu-117 Trastuzumab with magrolimab slowed tumor growth in animal models of solid tumors compared to either the radiolabeled Trastuzumab or magrolimab as single agents. Actinium Pharmaceuticals Inc. (NYSE: ATNM) is continuing to evaluate this combination in additional tumor models, and it intends to continue to study this combination with the goal of advancing to human clinical trials.(33)

ACTINIUM PHARMACEUTICALS INC. (NYSE: ATNM) HIGHLIGHTS (33)

  • Positive top-line results from the pivotal Phase 3 SIERRA trial p< 0 0001 for primary endpoint durable Complete Remission
  • Iomab-B addresses the initial market of 10,000 r/r AML patients who do not access potentially curative BMT with current approaches
  • Data supports continued expansion of targeted conditioning for BMT in other blood cancers and for cellular therapy and gene therapy indications
  • 1 year and 2 year OS data from Actimab A CLAG M combination trial compares favorably to current therapies for r/r AML patients and supports backbone therapy strategy in AML
  • Leadingedge innovation in radio pharma R&D drives partnerships including Astellas in solid tumor theranostics, first in class radiotherapy combinations in solid tumors including HER 3 with AVEO and EpicentRx with CD 47 immunotherapy
  • Strong balance sheet with over $111 million enables multiple milestones including SIERRA BLA filing/potential approval

RECENT NEWS

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones (27)

On February 6, 2023, Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. (40)

Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. (40)

The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium’s strategy of leveraging Actimab-A’s targeted radiotherapy mechanism to elicit synergistic effects. (40)

The CRADA studies will be overseen by NCI in collaboration with Actinium’s clinical development team. (40)

Through the CRADA, Actimab-A will be available at over 2,000 clinical trial sites under the Experimental Therapeutics Clinical Trials Network (ETCTN) and the National Clinical Trials Network (NCTN) that includes leading oncology network groups such as Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN), Southwest Oncology Group (SWOG) and the Alliance for Clinical Trials in Oncology. Actimab-A studies may also be conducted through NCI’s MyeloMATCH program. (40)

NCI Cancer Therapy Evaluation Program (CTEP), which sponsors approximately two thirds of all combination cancer studies, will be accepting Letters of Intent (LOIs) or concepts for Phase 1, 2 or 3 studies of Actimab-A in AML and other hematological malignancies. (40)

Sandesh Seth, Actinium’s Chairman and CEO, said, “We are incredibly honored to be collaborating with NCI and excited that they share our vision for Actimab-A’s potential for the treatment of AML and other blood cancers. The CRADA will allow Actimab-A’s broad applicability to be fully studied and developed by leading oncology network groups as well as NCI’s leading-edge MyeloMATCH program in ways Actinium could not do independently. NCI’s sponsorship will also allow us to accelerate novel Actimab-A combinations and broaden its use in AML and other hematological indications, while the collaboration with NCI, who funds and maintains the largest centralized clinical trial support systems in the United States, will help preserve our balance sheet for additional corporate priorities.” (40)

Dr. Avinash Desai, Chief Medical Officer of Actinium Pharmaceuticals, commented, “NCI’s broad support under the CRADA is a strong encouragement for us to together explore Actimab-A’s potential for the treatment of AML and other hematologic malignancies. As the only CD33 targeting radiotherapy in development, Actimab-A is uniquely positioned to address the challenges in treating relapsed or refractory AML patients who do not respond well to front line therapies and those whose disease stops responding to traditional cytotoxic or available targeted therapies. We are highly encouraged by the high rates of responses, minimal residual disease negativity and strong survival benefit at 1 and 2 years in heavily treated patients, including prior Venetoclax treatment and/or transplant, and those with adverse cytogenetics, including TP53 mutations, recently reported from the Actimab-A CLAG-M combination study. We look forward to working collaboratively with the NCI and all investigators through this CRADA to complete multiple clinical trials to further realize Actimab-A’s therapeutic potential.” (40)

THE MANAGEMENT TEAM

SANDESH SETH – CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD

Sandesh has 25+ years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Sandesh was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Sandesh has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Sandesh was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

MADHURI VUSIRIKALA, M.D. – VICE PRESIDENT, CLINICAL DEVELOPMENT BMT AND CELLULAR THERAPY

Madhuri is an accomplished bone marrow transplant physician and hematologist with over 20 years of clinical experience. She is board certified in internal medicine, hematology and oncology. Madhuri joins Actinium from UT Southwestern Medical Center in Dallas, Texas, where she has been a Professor of Internal Medicine in the Division of Hematology/Oncology and Medical Director of the Adult Allogeneic Bone Marrow Transplant Program. She specialized in managing a variety of hematologic malignancies and performing allogeneic bone marrow transplants for these patients when indicated. She also served as primary investigator for most of the clinical trials at UT Southwestern related to BMT. Madhuri earned her medical degree (M.B.B.S.) at India’s Lady Hardinge Medical College before completing an internal medicine internship at Maulana Azad Medical College-Delhi University and an internal medicine internship and residency at The State University of New York, Syracuse. She also completed a hematology and oncology fellowship at the University of Pittsburgh and an advanced fellowship in bone marrow transplantation at Vanderbilt University Medical Center. Madhuri is a member of the American Society of Hematology, American Society of Transplantation and Cellular Therapy. She serves as a member on the NCCN panels for Hematopoietic Cell Transplantation and Acute Lymphoblastic Leukemia committees.

PATRIK BRODIN, MSC, PH.D. – VICE PRESIDENT, HEAD OF RADIATION SCIENCES

Patrik is a board certified Medical Physicist, and a Diplomat of the American Board of Radiology in the discipline of Therapeutic Medical Physics, and previously, was an Assistant Professor and Senior Physicist at the department of Radiation Oncology at Montefiore/Einstein. By combining his expertise in radiation physics and data analysis with biology-based research methods, he spearheaded the development of new approaches in radiation-driven immunotherapy, and solutions for reducing the risk of severe treatment complications associated with receiving high-dose radiation therapy. Patrik has experience and expertise in clinical medical physics, biostatistics and advanced analytical methods including quantitative image analysis, and novel experimental design. He has authored more than 60 peer-reviewed publications and presented at national and international meetings including oral presentations at the ESTRO, ASTRO, AAPM and PTCOG annual meetings. Patrik trained in Medical Physics at Lund University, Sweden, followed by a PhD at the Niels Bohr Institute at the University of Copenhagen, Denmark, and received his M.Sc. in Clinical Research Methods from Yeshiva University upon coming to the United States.

AVINASH DESAI, M.D. – CHIEF MEDICAL OFFICER

Avinash is an industry veteran in the hematology and oncology field, most recently serving as Vice President, Head of U.S. Medical Affairs – Oncology at Glaxo Smith Kline (GSK). Over the course of his twenty-five-year career, Avinash successfully designed and implemented clinical development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data and Safety Monitoring Boards (DSMB) for hematology, oncology and therapeutic candidates. At GSK, he established the U.S. medical affairs oncology team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in ovarian cancer, and dostarlimab in endometrial cancer. In addition to GSK, Avinash has overseen the clinical development, implementation and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies, including Eli Lilly & Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc. Prior to GSK, he was the VP of Global Medical Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly’s GI Oncology portfolio. Earlier in his career, Avinash contributed to the approval of Janssen’s myeloma drug Darzalex® (daratumumab) and leading and strategically executing medical affairs activities globally for Velcade® (bortezomib). Prior to Janssen, Avinash was responsible for the international development of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials that led to NDA submission for Jevtana® (cabazitaxel).

DR. MARY MEI CHEN, M.D., PH.D. – VICE PRESIDENT, CLINICAL DEVELOPMENT

Mary leads clinical development programs in hematological malignancies and solid tumors at Actinium Pharmaceuticals, Inc. Prior to joining Actinium, she led multiple clinical trials including the global pivotal Phase 3 study of Uproleselan in AML as well as Phase 1 through Phase 3 clinical trials in patients with multiple myeloma, and solid tumors. She successfully led multidisciplinary teams in the submission of multiple INDs/Clinical Trial Application and participate multiple NDA applications in the US, EU, and other regions at Takeda Inc and Pfizer (Wyeth). She received training in both hematology (M.D.) and immunology (Ph.D.) followed by over twenty years of hematology oncology experience from academics and industry. Before moving her career to industry, she was a faculty, Instructor in Medicine, at Harvard Medical School, Brigham and Women’s Hospital. Mary received her Doctor of Medicine degree from Shanghai Jiao Tong University, School of Medicine. and her Ph.D. in Immunology from Chiba University, Graduate School of Medicine in Tokyo, Japan. She completed her postdoctoral fellowship in Harvard Medical School, Boston. Over the course of her career, she has authored over 60 peer reviewed publications in high impact journals.

NEWS

ACTINIUM TO PRESENT FULL RESULTS FROM PIVOTAL PHASE 3 IOMAB-B SIERRA TRIAL ON INVESTOR CALL FOLLOWING THE LATE-BREAKER PRESENTATION AT THE 2023 TRANSPLANTATION & CELLULAR THERAPY TANDEM MEETINGS ON SATURDAY, FEBRUARY 18, 2023 

FEB 14, 2023

ACTINIUM SIGNS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE TO FURTHER ENHANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF ACTIMAB-A FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA AND OTHER HEMATOLOGIC MALIGNANCIES 

FEB 6, 2023

ACTINIUM PHARMACEUTICALS, INC. TO PRESENT AT THE 3RD ANNUAL B. RILEY SECURITIES ONCOLOGY CONFERENCE 

JAN 17, 2023

ACTINIUM ANNOUNCES PHASE 3 IOMAB-B SIERRA DATA ACCEPTED FOR LATE-BREAKER PRESENTATION AT THE TRANSPLANTATION & CELLULAR THERAPY TANDEM MEETINGS 

JAN 12, 2023

ACTINIUM HIGHLIGHTS SURVIVAL DATA IN RELAPSED/REFRACTORY AML PATIENTS WITH PRIOR VENETOCLAX TREATMENT AND/OR WITH A TP53 MUTATION FROM THE ACTIMAB-A CLAG-M COMBINATION TRIAL ORAL PRESENTATION AT ASH 

DEC 12, 2022

ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES RESEARCH COLLABORATION WITH COLUMBIA UNIVERSITY TO STUDY ACTIMAB-A IN AML FOLLOWING TRANSPLANT OF ENGINEERED HEMATOPOIETIC STEM CELLS GENE EDITED TO BE CD33 NEGATIVE 

DEC 8, 2022

ACTINIUM ANNOUNCES POSITIVE 1-YEAR AND 2-YEAR OVERALL SURVIVAL DATA FOR PATIENTS WITH RELAPSED OR REFRACTORY AML IN PHASE 1 ACTIMAB-A CLAG-M COMBINATION TRIAL 

NOV 3, 2022

ACTINIUM APPOINTS SEASONED LEADER CAROLINE YARBROUGH AS CHIEF COMMERCIAL OFFICER TO SPEARHEAD IOMAB-B COMMERCIALIZATION 

NOV 2, 2022

ACTINIUM ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 SIERRA TRIAL OF IOMAB-B IN PATIENTS WITH ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA 

OCT 31, 2022

ACTINIUM EXPANDS CLINICAL LEADERSHIP TEAM TO SUPPORT KEY DEVELOPMENT PROGRAMS FOR IOMAB-B AND ACTIMAB-A 

OCT 27, 2022

ACTINIUM PHARMACEUTICALS TO PARTICIPATE IN THE 2022 BIO-EUROPE CONFERENCE 

OCT 26, 2022

ACTINIUM BOLSTERS ITS SENIOR LEADERSHIP TEAM AHEAD OF UPCOMING CLINICAL DATA FOR IOMAB-B 

OCT 25, 2022

ACTINIUM TO PRESENT AT THE CANTOR FITZGERALD ONCOLOGY, HEMATOLOGY & HEMEONC CONFERENCE 

SEP 26, 2022

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY TWO THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA LLC  FOR A ONE DAY ATNM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NASDAQ: HILS) Profile

Hillstream BioPharma, Inc.

OUR NEW PROFILE IS:   (NASDAQ: HILS)

      _________________

THIS HAS A FLOAT UNDER 4M & A MARKET CAP UNDER 8M ! ! !

HILS IS ON THE MOVE CLOSING GREEN 8 OUT OF THE LAST 10

RECENT COLLABORATION ALLOWS HILLSTREAM TO ENTER THE RAPIDLY GROWING IMMUNO-ONCOLOGY THERAPEUTICS MARKET

         ___________________

https://platform.twitter.com/embed/Tweet.html?dnt=false&embedId=twitter-widget-0&features=eyJ0ZndfdGltZWxpbmVfbGlzdCI6eyJidWNrZXQiOltdLCJ2ZXJzaW9uIjpudWxsfSwidGZ3X2ZvbGxvd2VyX2NvdW50X3N1bnNldCI6eyJidWNrZXQiOnRydWUsInZlcnNpb24iOm51bGx9LCJ0ZndfdHdlZXRfZWRpdF9iYWNrZW5kIjp7ImJ1Y2tldCI6Im9uIiwidmVyc2lvbiI6bnVsbH0sInRmd19yZWZzcmNfc2Vzc2lvbiI6eyJidWNrZXQiOiJvbiIsInZlcnNpb24iOm51bGx9LCJ0Zndfc2hvd19idXNpbmVzc192ZXJpZmllZF9iYWRnZSI6eyJidWNrZXQiOiJvbiIsInZlcnNpb24iOm51bGx9LCJ0ZndfbWl4ZWRfbWVkaWFfMTU4OTciOnsiYnVja2V0IjoidHJlYXRtZW50IiwidmVyc2lvbiI6bnVsbH0sInRmd19leHBlcmltZW50c19jb29raWVfZXhwaXJhdGlvbiI6eyJidWNrZXQiOjEyMDk2MDAsInZlcnNpb24iOm51bGx9LCJ0ZndfZHVwbGljYXRlX3NjcmliZXNfdG9fc2V0dGluZ3MiOnsiYnVja2V0Ijoib24iLCJ2ZXJzaW9uIjpudWxsfSwidGZ3X3ZpZGVvX2hsc19keW5hbWljX21hbmlmZXN0c18xNTA4MiI6eyJidWNrZXQiOiJ0cnVlX2JpdHJhdGUiLCJ2ZXJzaW9uIjpudWxsfSwidGZ3X3Nob3dfYmx1ZV92ZXJpZmllZF9iYWRnZSI6eyJidWNrZXQiOiJvbiIsInZlcnNpb24iOm51bGx9LCJ0ZndfbGVnYWN5X3RpbWVsaW5lX3N1bnNldCI6eyJidWNrZXQiOnRydWUsInZlcnNpb24iOm51bGx9LCJ0Zndfc2hvd19nb3ZfdmVyaWZpZWRfYmFkZ2UiOnsiYnVja2V0Ijoib24iLCJ2ZXJzaW9uIjpudWxsfSwidGZ3X3Nob3dfYnVzaW5lc3NfYWZmaWxpYXRlX2JhZGdlIjp7ImJ1Y2tldCI6Im9uIiwidmVyc2lvbiI6bnVsbH0sInRmd190d2VldF9lZGl0X2Zyb250ZW5kIjp7ImJ1Y2tldCI6Im9uIiwidmVyc2lvbiI6bnVsbH19&frame=false&hideCard=false&hideThread=false&id=1620432672853200896&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fhils1%2F&sessionId=14fdb8539a8bdac5430a90f5a062199d64ed73c9&theme=light&widgetsVersion=aaf4084522e3a%3A1674595607486&width=550px

Hello Everyone,

Did you get our last profile? It closed green that day and again 6 of the next 7 sessions.  We kicked off January with a 25% overnight winner and it has been all gravy since then.  Most of our profiles have gone on to move double digits from the opening trade the days we brought them to you.  Let’s hope that February is another quality month. The markets certainly are erratic right now as evidenced by today’s big spike on the Nasdaq and small pullback on the Dow.  It is hard to make heads or tails of what’s going on.  No matter what state the market is in there are always opportunities worth researching.

This next one has been on the move since the second half of January.  The company put news out the other day and as you can see the stock went nuts.

There is no doubt that HILS is on the move closing green 8 out of the last 10.  One of the factors that could be playing a major part in HILS recent success is it’s structure itself.  Yahoo has the Market cap under 8M and a float under 4M.  It moved another 7% today even after the huge session it had on the 31st with well over 100M exchanging hands on the session.  I LIKE THAT.

Hillstream Biopharma is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers.   Hillstream’s most advanced candidate, HSB-1216, expected to enter clinical trials in 2023, targets ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, whose active drug was found to be efficacious in a clinical pilot study in Germany in drug resistant tumors, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to initiate IND discussions with the FDA in first half of 2023. Hillstream uses Quatramer™, a proprietary tumor targeting platform which extends duration of action and minimizes off-target toxicity, with HSB-1216 as well as biologics, mRNA, peptides and other modalities in the tumor microenvironment. Quatrabody™ conjugates immuno-oncology targets with greater binding affinity than approved therapies. Hillstream Quatramers with novel biologics developed against proprietary undruggable epitopes of PD-1 and other validated will enter the rapidly growing immuno-oncology therapeutics market leading with HSB-1940, targeting PD-1, followed by additional targets including PD-L1, HER-2, TROP-2 and now MUC1-C.

The news that sent HILS bonkers on Tuesday was huge and the market reacted:

HILLSTREAM BIOPHARMA SIGNS AN EXCLUSIVE OPTION AGREEMENT TO ADVANCE NEXT-GENERATION ANTI-MUC1-C AGENTS FOR DRUG RESISTANT CANCERS

Development expected to capitalize upon tumor targeting Quatramers™

MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC)

BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein.

The MUC1 gene was identified by Dr. Donald Kufe, Distinguished Physician and Researcher at Dana-Farber and based on its overexpression in human cancers. Dr. Kufe’s long-standing work has supported the premise that prolonged activation of MUC1-C in settings of chronic inflammation promotes cancer.

Dr. Kufe has demonstrated that MUC1-C is necessary for multiple hallmarks of the cancer cell, including (i) the persister cell (PC) state, (ii) drug resistance, (iii) immunosuppression, and (iv) poor clinical outcomes. Importantly, he has found a marked MUC1-C dependency for cancer stem cells (CSCs) derived from highly aggressive TNBCs, SCLCs, MCCs and NEPCs. Based on these findings, MUC1-C has emerged as an exceptional target for cancer treatment with agents developed in the Kufe laboratory.

Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis. This approach combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long term responses and cures.

“We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber,” said Randy Milby, CEO of Hillstream. “This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients.”

  ____________

https://platform.twitter.com/embed/Tweet.html?dnt=false&embedId=twitter-widget-1&features=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&frame=false&hideCard=false&hideThread=false&id=1620435268342874116&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fhils1%2F&sessionId=14fdb8539a8bdac5430a90f5a062199d64ed73c9&theme=light&widgetsVersion=aaf4084522e3a%3A1674595607486&width=550px


Quatramer Platform

Quatramer is tumor-targeted platform with capacity to deliver drug and biologic combinations

Quatramer is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer drug candidates using our Quatramer platform.

Quatramer based compounds with therapeutic cargoes from our product pipeline include DNA-based contents which hijack the tumor’s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as TNF-alpha and potentially others. The platform’s tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses in order to eradicate rare cancers and treatment resistant tumors with minimal or no treatment options.

TridentAI Platform

Trident is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity

Trident, as the name suggests, takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely Epithelial-to-mesenchymal transition, Dedifferentiation/Transdifferentiation, and Transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC), but also human cancer proteome datasets from emerging global efforts that include Human Cancer Proteome Project (HUPO; Cancer-HPP), The Cancer Proteome Atlas (TCPA) and The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). Inclusion of proteomics data is very critical for identifying dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the genomic and transcriptomic level alone.

Trident is a Deep Learning Engine that integrates in vitro and in vivo epigenetic, transcriptomic and proteomic data characterizing genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:

Biomarker fingerprints that deconvolve a heterogeneous tumor biopsy into a discrete phenotypic state along a gradient of progressive cellular plasticity, Network of dis-regulated functional pathways that underscore a patient’s pathology, and Indication-specific synthetic-lethal sensitivities to drugs

Trident utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic profiles thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select indications.

Trident maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale

Trident traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum and enable quantification of degree of plasticity along the trajectory. Trident’s Deep Learning Engine trains a model that can reduce this high-dimensional information into a one-dimensional quantitative and measurable scale which informs what is the degree of plasticity in a biopsy sample or cell line dataset. Trident’s unbiased search in the vast repository of multi-modal datasets enables identification of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This biomarker-guided, state-specific approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete phenotypic state along a gradient of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.

Trident is designed to de-risk clinical development and deliver on the promise of precision medicine

Trident is designed to deliver on Hillstream Bio’s ultimate goal, which is to identify and treat the right patients that are most likely to benefit from treatment. Using Trident, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity for a specific patient, which will then directly inform about a patient’s sensitivity to activation/inhibition of the synthetically lethal target and probability of successful treatment. More than just de-risking clinical development, Trident aspires to deliver on the promise of precision medicine by building a platform based on the robust foundation of patient-based biomarker research and deep learning artificial intelligence technologies.

The Hillstream Biopharma Pipeline

image

HSB-1216: Novel Inducer of Iron-Mediated Cell Death

Iron is a central player in cancer progression and metastasis and dysregulated in tumors. Certain cancer cells rely on an increased labile iron pool (LIP) which fosters tumor growth, metastasis and relapse. HSB-1216 (Hillstream’s lead compound) normalizes the LIP in tumors and causes cell death by de-linking cancer’s addiction to iron. HSB-1216, is a novel and potent inducer of a powerful mechanism involving iron-mediated cell death. This process which sequesters iron in lysosomes allows HSB-1216 to cause lysosomal membrane permeabilization of hard-to-treat cancer cells – causing them to rupture and stop replicating. An area of interest for the development of HSB-1216 are rare cancers with high unmet need.

image

HSB-1216 is for multiple, therapy resistant or high unmet need solid tumors. HSB-1216 exploits a key feature of certain tumors that rely on an excessive LIP within the cell to modify the dysregulated iron microenvironment of cancer. In our Phase 1 study we intend to test HSB-1216 in a variety of solid tumors. Although we have received orphan drug designation (ODD) in small cell lung cancer for HSB-1216’s active drug, we may pursue ODD in multiple indications. HSB-1216 has the potential to be used in cancer patients who have failed standard-of-care therapies in solid tumors. HSB-1216 is being advanced to alleviate these devastating consequences due to a lack of therapies.

HSB-888: Novel Inducer of Iron-Mediated Cell Death + Ultra Low-Dose Anthracycline

The components of HSB-888 are two anticancer drugs with distinct and complementary mechanisms of actions which together constitute an active combination for treating sarcomas. Hillstream investigated whether the efficacy of this combination could be improved by controlling drug ratios following in vitro and vivo administration. The combinations were evaluated systematically for drug ratio-dependent synergy in vitro using multiple tumor cell lines. In vitro screening informatics on drug ratio-dependent cytotoxicity identified a consistently antagonistic region between payloads at various molar ratios, which also showed multiple synergistic ratios, dependent on the chemical characteristics of either DNA intercalating payload combined with an inducer of iron-mediated cell death.

image

Co-formulations of these two agents were developed that maintained a fixed drug ratio for stability and release profiling over broad timelines. Drug ratio-dependent antitumor activity was demonstrated in vitro and in vivo for these ratios and improved antitumor activity was observed for a specific molar ratio of DNA intercalator:inducer of iron-mediated cell death (designated HSB-888) compared to drug cocktails in models tested. HSB-888, is a fixed-ratio formulation of DNA intercalator:inducer of iron-mediated cell death, and a lead near-clinical candidate for development in multiple sarcomas.

HSB-510: Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

HSB-510 is a novel highly targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate c-myc, a highly pursued and yet undruggable cancer drug target. The Quatramer platform achieves optimal tumor targeting and bioavailability of the highly potent targeted small molecule. HSB-510’s active drug, in co-development via a Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences, part of the National Institutes of Health, induced necrosis in several mutant and FLT3-resistant acute myeloid leukemia (AML) cell lines and primary blasts from AML patients, while showing no cytotoxicity against several normal cells. The FLT-3 gene is associated with high risk of relapse and poor clinical outcomes upon treatment with conventional chemotherapy in AML patients. Target specific engagement of PI3K-delta and HDAC6 was further demonstrated using the cellular thermal shift assay. HSB-510 also showed ideal pharmacokinetic properties in mice via intraperitoneal administration which provides a means to examine the biological effects of inhibiting these two enzymes with a single molecule, either in vitro or in vivo.

image

HSB-114: TNF-alpha DNA

HSB-114 is a novel immunotherapeutic agent which uses our proprietary Quatramer technology to deliver tumor necrosis factor-alpha (TNF-alpha or TNF-α) gene into cancer cells. Previous immunotherapeutic strategies used adenovector technology requiring replication deficient gene deletions and complex manufacturing controls in order to deliver the TNF-alpha gene, but posed a theoretical risk of systemic toxicity and adjacent tissue damage due to overflow of TNF-alpha in blood from the tumor, resulting in some dose-limiting toxicities. We believe our novel non-viral immunotherapeutic TNF-alpha gene therapy, HSB-114, builds on the previous clinical development program with improved scalability and tunability to treat metastatic soft tissue sarcomas.

image

https://platform.twitter.com/embed/Tweet.html?dnt=false&embedId=twitter-widget-2&features=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&frame=false&hideCard=false&hideThread=false&id=1617556564130283520&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fhils1%2F&sessionId=14fdb8539a8bdac5430a90f5a062199d64ed73c9&theme=light&widgetsVersion=aaf4084522e3a%3A1674595607486&width=550px

HILLSTREAM BIOPHARMA ANNOUNCES DEVELOPMENT OF PROPRIETARY TARGETED BIOLOGICS, KNOB QUATRABODIES™ (HSB-1940) AGAINST PD-1, BY COMBINING QUATRAMERS™ WITH OMNIAB’S PICOBODIES™, VIA A COLLABORATION AGREEMENT, AGAINST NOVEL, UNREACHABLE AND UNDRUGGABLE EPITOPES IN HIGH VALUE VALIDATED TARGETS

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market

By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940, is being developed to target PD-1

Picobodies are the smallest known antibody fragment, comprised of ultra-long CDR H3 sequences of 30-40 amino acids rich with cysteines that create tightly folded structures capable of binding recessed epitopes

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

The technologies of Hillstream and Minotaur will be combined under a previously disclosed license from OmniAb to discover, develop and advance biotherapeutics against high-value validated targets. Picobodies are antibody “knob” domains comprised of cysteine-rich ultralong complementary determining region (CDR) H3 sequences of 30-40 amino acids, which have the potential to access challenging epitopes better than full size antibodies can.

By combining Quatramers with their long half-life coated with a PD-1 Picobody™to create HSB-1940, Hillstream believes it could more efficiently target novel epitopes with greater binding affinity than approved biologics. Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.

Dr. Vaughn Smider, Founder and Chief Executive Officer of Minotaur, stated, “We are excited to contribute our expertise to help in combining OmniAb’s OmniTaur-derived ultralong CDR H3 antibody fragments and Hillstream’s tumor-targeting Quatramers to discover and develop novel next-generation targeted cancer therapeutics.”

Antibodies derived from mouse or human sources use the surface formed by complementarity determining regions (CDRs) on the variable regions of the heavy chain/light chain heterodimer, which typically forms a relatively flat binding surface. Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site. However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains. Meanwhile, in bovines, ultralong CDR-H3 regions form an independently folding mini-domain, which protrudes far out from the surface of the antibody and forms a “stalk and knob” structure which is diverse in both its sequence and disulfide patterns. The “knob” (Picobody) component can be expressed as an independent antigen binding domain. At ~4-6 kDa, these are three times smaller than a camelid “nanobody”, and are the smallest known antibody fragment. These atypical antigen binding sites of bovines potentially provide the ability to interact with different antigenic determinants, particularly recessed or concave surfaces, compared to traditional antibodies.

Randy Milby, Chief Executive Officer of Hillstream, stated, “The Picobodieswhich OmniAb brings to this collaboration combined with our Quatramers to create a novel and disruptive Knob Quatramer platform will be a great addition to our portfolio starting with HSB-1940. We are doubly excited that Dr. Vaughn Smider, a pioneer in the discovery, engineering and understanding of these unique proteins, will be leading Minotaur’s services. The Quatramer is a key Hillstream platform which is now poised to create novel therapeutics using “smart carriers” with multiple approaches for enhancing targeted cancer immunotherapy.”

NEWS

  • GlobeNewswire•2 days agoHILLSTREAM BIOPHARMA SIGNS AN EXCLUSIVE OPTION AGREEMENT TO ADVANCE NEXT-GENERATION ANTI-MUC1-C AGENTS FOR DRUG RESISTANT CANCERSDevelopment expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC) BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a biotechnology company developing novel therapeutic candidates targeting fe
  • GlobeNewswire•16 days agoHILLSTREAM BIOPHARMA TO PRESENT AT THE VIRTUAL SIDOTI MICRO-CAP CONFERENCE ON JANUARY 18-19, 2023BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023. Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPhar
  • GlobeNewswire•2 months agoHILLSTREAM BIOPHARMA ANNOUNCES DEVELOPMENT OF PROPRIETARY TARGETED BIOLOGICS, KNOB QUATRABODIES™ (HSB-1940) AGAINST PD-1, BY COMBINING QUATRAMERS™ WITH OMNIAB’S PICOBODIES™, VIA A COLLABORATION AGREEMENT, AGAINST NOVEL, UNREACHABLE AND UNDRUGGABLE EPITOPES IN HIGH VALUE VALIDATED TARGETSCollaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940, is being developed to target PD-1 Picobodies are the smallest known antibody fragment, comprised of ultra-long CDR H3 sequences of 30-40 amino acids rich with cysteines that create tightly folded structures capable of binding recessed epitopes BRIDGEWATER, N.J.
  • GlobeNewswire•2 months agoHILLSTREAM BIOPHARMA TO PRESENT AT THE RHK CAPITAL DISRUPTIVE GROWTH CONFERENCE ON DECEMBER 5-6, 2022BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022. Mr. Randy Milby, Founder and Chief Exe
  • GlobeNewswire•4 months agoHILLSTREAM’S NEW ANTI-CANCER MECHANISM QUATRAMER-BASED FERROPTOSIS INDUCER, HSB-1216 ABSTRACT AVAILABLE FOR VIEWING AT EORTC-NCI-AACR SYMPOSIUMAbstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growthBRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (“Hillstream”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that an abstract highlighting the progress of the Quatramer-based Ferroptosis Inducer, HSB-1216, are ava
  • GlobeNewswire•4 months agoHILLSTREAM BIOPHARMA, INC. TO PRESENT AT UPCOMING INVESTOR CONFERENCESBRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences: Ev
  • GlobeNewswire•5 months agoHILLSTREAM BIOPHARMA TO PARTICIPATE IN THE FIERCE BIOTECH SUMMIT ON SEPTEMBER 19-20BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, will participate in the Fierce Biotech Summit, being held at The Westin Copley Place in Boston, on September 19-20, 2022. Mr. Randy Milby, Founder and Chief Executi
  • GlobeNewswire•7 months agoHILLSTREAM BIOPHARMA TO ATTEND THE 12TH ANNUAL WORLD ORPHAN DRUG CONGRESS USA ON JULY 11-13BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022. Mr. Randy Milby, Founder a
  • GlobeNewswire•7 months agoHILLSTREAM BIOPHARMA ANNOUNCES COLLABORATION WITH SAPIEN BIOSCIENCES IN CANCER TREATMENTSInvestigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluat
  • GlobeNewswire•8 months ago

MANAGEMENT  

RANDY MILBY – CEO & CHAIRMAN

Mr. Milby was the former Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. A seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.

THOMAS HESS CPA – CHIEF FINANCIAL OFFICER

Thomas Hess is an experienced financial expert. From August 2014 until June 2021, Mr. Hess served as Chief Financial Officer and Senior Vice President of Finance of Genomind, Inc., a mental health company that developed and sold a pharmacogenomic test that analyzed how an individual’s genes may affect medication outcomes. From September 2011 until its sale in April 2014, Mr. Hess served as Chief Financial Officer and Executive Vice President of Finance of The Keane Organization, a comprehensive provider of unclaimed property services. Mr. Hess also previously served in various other capacities including, but not limited to, Chief Financial Officer and Senior Vice President of Yaupon Therapeutics, Inc.; Chief Financial Officer and Vice President, Finance of Adolor Corporation; Corporate Controller of Vicuron Pharmaceuticals, Inc.; and Senior Manager – Accounting and Audit of KPMG. Mr. Hess was formerly an adjunct faculty member/lecturer at Pennsylvania State University and DeSales University. Mr. Hess received his B.S. in accounting from The Pennsylvania State University and his MBA from Katz Graduate School of Business, University of Pittsburgh. Mr. Hess is a Certified Public Accountant in the state of Pennsylvania. He currently serves on the Alumni Council of Penn State and is the Chairman of the Nittany Lion Club Annual Fund.

RON WEITZMAN, MD – CLINICAL DEVELOPMENT

Ron is a US trained board certified medical oncologist having worked in the biopharmaceutical industry since 1999. Over his career, Ron has worked in all areas of clinical development including phase 1, 2 and 3 clinical trials. He has drug development experience in both solid and hematological malignancies and has interacted extensively with FDA, EMEA, Canadian and Japanese health authorities. In his most recent role at Exelixis, he oversaw cabozantinib’s (XL184) development in prostate cancer with two ongoing phase 3 registrational studies underway. Over the years, Ron has managed both large and small groups and very much enjoys mentoring colleagues.

BARRY ROSENBLATT, PHD – MANUFACTURING

Dr. Korczak is a translational science executive with established track record of developing drugs from discovery through IND and into clinical Proof of Concept (POC) studies. She has an excellent knowledge of drug discovery, pharmacology, pharmacokinetics (PK), toxicology, manufacturing of drug substance/product, early clinical development and regulatory requirements. Her leadership in start-up and early stage biotechnology companies resulted in accelerated drug development across multiple therapeutic areas including oncology, dermatology, inflammatory diseases, cardiology, and infectious diseases.

GAUTAM GOEL, PHD. – DATA SCIENCE

Gautam Goel is an expert computational biologist and a seasoned biotech professional with an impactful 15-year track record enabling clinical development of precision medicines. Gautam advises biotech and pharmaceutical companies on challenges in early-stage target discovery, lead candidate drug identification, and biomarker analysis for clinical development. Gautam has enabled his clients to raise tens of millions of dollars in collaborations with strategic pharmaceutical companies on the basis of machine-learning based target and drug discovery pipelines that he has helped design and build. Previously, he spearheaded cross-functional R&D operations as Director of Precision Medicine at a biotech startup to accelerate path to clinical development for an Antigen-specific Immunotherapy for Type 1 Diabetes (Discovery to FIH studies in 3 years). Simultaneously, he led the biomarker discovery program in Celiac Disease which resulted in the 1st blood-based diagnostic for patients on gluten-free diet. Additionally, he developed an immune response monitoring toolkit to support Phase 2 clinical trials for an antigen-specific peptide vaccine to treat Celiac disease. Prior to that, Gautam was a Research Fellow at Massachusetts General Hospital in Boston where he investigated mechanisms of IBD pathogenesis and discovered druggable targets and drug candidates. Gautam’s work has led to over 40 publications in disease areas including Crohn’s disease, Ulcerative Colitis, Celiac Disease, Chronic Inflammation and Infectious diseases. His technical expertise includes Antigen-specific Immunotherapy, Systems Immunology, Dynamical Systems Theory, Time-Series Data Analysis, Machine Learning, Deep Learning and Big Data Analytics & Systems Biology (Single cell analysis, RNA-seq, CyTOF, Nanostring, Proteogenomics, Metabolomics, Immunophenotyping).

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA LLC  FOR A ONE DAY HILS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.